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Summary 
Regulation of adipose cell mass is a critical homeo- 
static process in higher vertebrates. The conversion 
of fibroblasts into cells of the adipose lineage is in- 
duced by expression of the orphan nuclear receptor 
PPART. This suggests that an endogenous PPARy li- 
gand may be an important regulator of adipogenesis. 
By assaying arachidonate metabolites for their capac- 
ity to activate PPAR response elements, we have iden- 
tified 15-deoxy-A12~14-prostaglandin J2 as both a PPARy 
ligand and an inducer of adipogenesis. Similarly, the 
thiazolidinedione class of antidiabetic drugs also bind 
to PPARy and act as potent regulators of adipocyte 
development. Thus, adipogenic prostanoids and anti- 
diabetic thiazolidinediones initiate key transcriptional 
events through a common nuclear receptor signaling 
pathway. These findings suggest a pivotal role for 
PPART and its endogenous ligand in adipocyte devel- 
opment and glucose homeostasis and as a target for 
intervention in metabolic disorders. 
Introduction 
Obesity, an excessive accumulation of adipose tissue, is 
a common disorder that affects over 30% of Americans 
(Kuczmarski et al., 1994). Its increasing prevalence is of 
concern, because excess adipose tissue is associated 
with the development of serious medical conditions, in- 
cluding noninsulin-dependent diabetes mellitus (NIDDM), 
hypertension, coronary artery disease, hyperlipidemias, 
and certain malignancies (Grundy and Barnett, 1990). A 
detailed understanding of the molecular events that con- 
trol adiposity is essential for the development of rational 
treatments for these disorders. 
Obesity is characterized by an increase in the number 
or size of adipocytes, or both (Flier, 1995). In addition to 
serving as a site for regulated storage and release of fatty 
acids, the adipocyte contributes to the regulation of food 
intake and energy balance through the production of lep- 
tin, the product of the obese gene (Campfield et al., 1995; 
Halaas et al., 1995; Pelleymounter et al., 1995). The adipo- 
cyte may also influence glucose homeostasis through the 
production of tumor necrosis factor a (TNFa) (Hotamisligil 
and Spiegelman, 1994) and other molecules. One of the 
earliest events in the differentiation of an adipocyte is the 
expression of they isoform of the peroxisome proliferator- 
activated receptor (PPARy) (Chawla et al., 1994; Tontonoz 
et al., 1994b). Indeed, forced expression of PPARr in fibro- 
blasts initiates a transcriptional cascade that leads to the 
development of the adipocyte phenotype (Tontonoz et al., 
1994c). This implies that signals that modulate PPARy 
activity may serve a primary role in regulating energy ho- 
meostasis. 
PPARy is a member of the nuclear receptor superfamily 
that includes receptors for the steroid, thyroid, and retinoid 
hormones (Evans, 1988). Like other members of this su- 
perfamily, PPARy contains a central DNA-binding domain 
(DBD) that binds to c&-acting elements (hormone re- 
sponse elements [HREs]) in the promoter of its target 
genes. PPARy response elements (PPRE) are composed 
of a directly repeating core site separated by one nucleo- 
tide (NNN-AGGTCA-N-AGGTCA) (Kliewer et al., 1992; 
Palmer et al., 1995). To recognize a PPRE, PPARy must 
form a heterodimer with the 9-cis retinoic acid receptor 
(RXR) (Figure 1 A). 
Once bound to an HRE, nuclear receptors activate tran- 
scription through their conserved C-terminal ligand- 
binding domains (LBD), which bind hormones with high 
affinity and specificity (Figure 1A) (Evans, 1988; Forman 
and Samuels, 1990). A growing number of nuclear recep- 
tor-related proteins (orphan receptors) have been identi- 
fied that possess LBD-like structures but that lack known 
ligands. The search for ligands for these newly discovered 
orphan receptors has lead to the discovery of previously 
unknown signaling pathways (Forman et al., 1995a; Hey- 
man et al., 1992; lssemann and Green, 1990; Levin et al., 
1992). Although natural ligands have not been identified 
for any isoform of PPAR, the a isoform is activated by a 
variety of synthetic peroxisome-proliferating agents as 
well as by long-chain fatty acids (Gottlicher et al., 1992; 
Gulick et al., 1994; lssemann and Green, 1990; Keller et 
al., 1993). In contrast, these agents do not generally serve 
as effective activators of PPARy (Kliewer et al., 1994; 
B. M. F. and R. M. E., unpublished data). However, one 
compound has been identified that can both activate 
PPARy (Kliewer et al., 1994) and induce adipogenesis 
(Tontonoz et al., 1994c). This compound, LY171883, is a 
synthetic leukotriene D4 receptor antagonist (Marshall et 
al., 1987) and competitive inhibitor of carnitine palmitoyl- 
transferase (Foxworthy and Eacho, 1988). Since 
LY171883 has structural features that mimic these lipids, 
it is possible that eicosanoid-like molecules could serve 
as natural ligands for PPARy. 
We have examined arachidonate metabolites for their 
ability to activate PPRE containing reporter constructs and 
have identified 15-deoxy-A12, “‘-prostaglandin Ja (15d- 
PGJ2) as a natural PPARy ligand. This prostanoid activates 
PPARy-dependent adipogenesis and thus represents a 
primary adipogenic signal. We also show that a class of 
antidiabetic agents (thiazolidinediones) act as 1 Sd-PGJa 
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Figure 1. Activation of the PPRE by PGDz Metabolites 
(A) Schematic model of PPAR-RXR heterodimers. The heterodimer 
is shown bound to a PPRE consisting of a direct repeat separated by 
one nucleotide. Each DBD contacts one core site (right arrow) within 
the direct repeat. By itself, PPAR exhibits a low affinity for DNA; high 
affinity binding requires heterodimerization with RXR. In addition to 
binding ligand, the LBD also possesses a dimerization and transactiva- 
tion function. 
(B) PGD2 metabolites activate the PPRE reporter in CV-1 cells. The 
reporter construct containsthree copies of the acyl-CoAoxidase PPRE 
cloned upstream of the TK-LUC reporter. CV-1 cells were transfected 
with the PPRE x 3 -TK-LUC reporter (300 ngll O5 cells) and the inter- 
nal control, CMX+gal(500 ngll O5 cells). Cells were treated for approx- 
imately40 hrwith mediaor mediacontaining the indicatedcompounds. 
Normalized luciferase activity was determined and plotted as fold acti- 
vation relative to untreated cells. The final concentrations of each 
compound were as follows: arachidonic acid, 30 NM; prostaglandins, 
10 FM; Wyl4,843, 5 PM; LG89, 100 nM. At the concentrations that 
were used, Wy14,643 and LG69 elicited maximal activation of PPARa 
and RXRa, respectively. 
analogs that also bind and activate PPARy. These results 
suggest a specific molecular linkage between 15d-PGJz, 
adipogenesis, and NIDDM and thus identify novel and un- 
expected avenues of prostanoid research. 
Results 
Prostaglandin J2 Derivatives Activate a PPRE 
During a search for fatty acid activators of PPARa, we 
noticed that in CV-1 ceils, arachidonic acid activated a 
PPRE reporter in the absence of a cotransfected receptor 
(Figure 1B; data not shown). This raised the possibility 
that products of arachidonic acid metabolism may activate 
the PPRE through an endogenous receptor. Accordingly, 
we tested the capacity of several eicosanoid derivatives 
to substitute for arachidonic acid. As illustrated in Figure 
1 B, the PPRE reporter was efficiently activated by PGD, 
and PGJ;! derivatives, but not by other prostanoids or leu- 
kotrienes (data not shown). Since PGD2 is a metabolic 
precursor to PGJ2 and its derivatives (see Figure 3A) (Fu- 
kushima, 1990), these results suggest that a prostaglandin 
of the J2 series may be a specific activator of the PPRE. 
The response to lSd-PGJ2 appeared to be dependent 
upon a nuclear hormone receptor, since it could be inhib- 
ited by overexpression of calreticulin (data not shown), a 
calcium-binding protein that can inactivate nuclear recep- 
tors (Burns et al., 1994; Dedhar et al., 1994). Moreover, 
expression of dominant negative RXR mutants (Forman 
et al., 1995b) also blocked the 15d-PGJ2 response (data 
not shown), suggesting that PGJ2 signaling is mediated 
by a nuclear receptor that heterodimerizes with RXR. To 
gain further insight into the nature of this response, we 
tested a wide variety of natural and synthetic HREs for 
their ability to respond to 15d-PGJ2. We found that the 
PPRE was uniquely responsive to ISd-PGJ2. No activity 
was seen with other HREs, including the DRl that com- 
prises the RXR response element of the cellular retinol- 
binding protein type II gene(Mangelsdorf et al., 1991) (data 
not shown). The PPRE used in these studies is derived 
from the acyl-CoA oxidase promoter and has previously 
been shown to be a functional response element for 
PPARa-RXR heterodimers (Kliewer et al., 1992). To ex- 
amine whether these receptors were present at levels suf- 
ficient to mediate the PGJ, response, cells were treated 
with Wyl4,643, a potent and selective activator of PPARa 
(Kliewer et al., 1994), or with LG69, a selective activator 
of RXR (Boehm et al., 1994). The inability of Wyl4,643 
and LG69 to activate the PPRE (Figure 1 B) indicates that 
the transcriptional activity of PGJ2 is not mediated by en- 
dogenous PPARa or RXR. 
Prostaglandin Jz Derivatives Activate PPARy 
We explored the possibility that the 15d-PGJn response 
could be mediated by other PPAR isoforms that may be 
expressed in CV-1 cells. Northern blot analysis revealed 
that these cells express PPARy and PPARS transcripts, 
but no detectable PPARa mRNA (data not shown). We 
therefore tested whether specific PPAR isoforms were re- 
sponsive to PGJn-related prostanoids. However, since the 
PPRE is strongly activated by the endogenous receptor, 
we could not adequately address this issue with the PPRE 
reporter. To establish an assay for PPAR activity without 
interference from the endogenous receptor, we created 
chimeric PPARs that activate transcription through a het- 
erologous response element. Fusion proteins were con- 
structed containing the yeast GAL4 DBD (Sadowski and 
Ptashne, 1989) linked to the LBD of either PPARa, PPAR?, 
or PPARG (GAL-PPARa, GAL-PPARy, or GAL-PPARG). 
When a reporter containing a GAL4 upstream activating 
sequence (UASG) is utilized, these chimeric receptors 
allow PPAR activity to be assayed independently of endog- 
enous receptors. With this approach, we found that PGD2 
and its PGJ2 metabolites were strong activators of GAL- 
PPARy but were poor activators of GAL-PPARa and S 
(Figure 2A). The hierarchy of response of PPARy to these 
and other prostanoids was similar to the pattern previously 
observed with the endogenous receptor (see Figure 1 B). 
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Figure 2. Prostaglandin J2 Derivatives Activate PPARy 
(A) Activation of GAL-PPAR LBD fusion proteins by PGJl derivatives. 
The reporter constructs contained four copies of the UASG cloned 
upstream of the TK-LUC reporter. CV-1 cells were transfected with 
UA& x 4 TK-LUC (300 ng/105 cells), CMX-8gal (500 ng/105 cells) 
and CMX-GAL-PPARa, CMX-GAL-PPAFty, or CMX-GAL-PPARG 
LBD (100 ng/105 cells). Following transfection, cells were treated with 
the following concentrations of each prostaglandin: 3 uM (PGD*, PGJ,, 
A’*-PGJ2, 15d-PGJ2, PGB,); 10 uM (PGEP, PGF?,, Sa,llf%PGF,). Nor- 
malized luciferase activity was determined and plotted as fold activa- 
tion relative to untreated cells. 
(B) Activation of PPAR LBDs tethered to GAL-RXR. CV-1 cells were 
treated as above, except that CMX-GAL-PPARa, CMX-GAL-PPARy, 
or CMX-GAL-PPARG LBD was replaced with CMX-GAL-RXR (100 
ng/105 cells), with our without CMX-PPARa, CMX-PPARy, or CMX- 
PPARG LBD (100 ng/105 cells). Normalized luciferase activity was de- 
termined and plotted as fold activation relative to untreated cells. 
l&i-PGJ2 Is the Most Active Metabolite of PGD2 
The conversion of arachidonic acid into prostanoid metab- 
olites has been studied in detail (Fukushima, 1990; Smith 
et al., 1991) and is outlined in Figure 3A. A comparison 
of this biosynthetic pathway with the activation profile of 
Figure 2A reveals that PPARy activation is mediated exclu- 
sively by metabolites of PGDz, the most active of which 
is the terminal metabolite 1 5d-PGJ2. Transcriptional acti- 
vation by metabolic precursors is reminiscent of the activa- 
tion of RXR by all-trans retinoic acid (at-RA). To activate 
RXR, at-RA must first be converted to the true activator: 
9-cis retinoic acid (Sc-RA) (Heyman et al., 1992; Levin et 
al., 1992). Thus, activation of an RXR-responsive reporter 
is seen within 2 hr of addition of the Sc-RA ligand. The 
at-RA precursor requires an extended exposure, during 
which time at-RA is metabolized to Sc-RA(data not shown). 
To see whether metabolic activation may be required for 
PGDz activity, we examined the kinetics of PPARy activa- 
tion by PGD, metabolites. Cells expressing GAL-PPARy 
were sampled at multiple time points after prostanoid addi- 
tion (Figure 38). PGD2 exhibited minimal activity during 
the first 7 hr of treatment and displayed significant activity 
only after a prolonged exposure to cells. Activation by 
PGJ2 and A’*-PGJ2 was seen after 4 hr of exposure to cells 
(data not shown). In contrast, 15d-PGJ2 rapidly activated 
PPARy; activation was first seen within 2 hr of treatment 
and was near maximal by 7 hr. These findings suggest 
that 15d-PGJ2 may be an’authentic PPARy activator. 
In both cases, 15d-PGJn was the most active prostanoid, 
achieving its most efficacious effects through the y iso- 
form. Since PGJn-related metabolites did not activate 
RXR, VDR, T,R, RAR, or several orphan receptors (data 
not shown), these data indicate that PGJ2 signaling is pref- 
erentially mediated by PPARy. 
Dose-response studies were performed as an addi- 
tional test of the relative activity of each PGD? metabolite. 
15d-PGJn exhibited the most potent response of all 
prostanoid activators (Figure 3C), lending further support 
for a fundamental role of 15d-PGJ2 in PPARy activation. 
PPARs normally function as heterodimers with RXR. Synthetic Thiazolidinediones Activate PPARy 
Therefore, we examined the ability of PGJa-related metab- The ability of 1 Sd-PGJ, to activate PPREs is reminiscent 
olites to activate the heterodimeric complex. This is an of the properties of pioglitazone (see Figure 8) an antidia- 
important issue, since ligand responsiveness can be dra- betic drug of the thiazolidinedione class (Sohda et al., 
matically altered by heterodimerization (Forman et al., 1990) that can activate the aP2 (adipocyte fatty acid-bind- 
1995b; Kurokawa et al., 1994). For example, high affinity ing protein) gene PPRE (Harris and Kletzien, 1994; Tonto- 
ligand binding by the insect ecdysone receptor is observed noz et al., 1994a, 1994b). Interestingly, pioglitazone 
only in the context of an ecdysone receptor-ultraspiracle shares a common para-ethoxy-phenyl backbone with the 
heterodimer (ultraspiracle is the insect homolog of RXR) weak PPARy activator LY171883 (see Figure 8) (Kliewer 
(Yao et al., 1993). The responsiveness of PPAR-RXR het- et al., 1994). This led us to examine the possibility that 
erodimers was examined by expressing a GAL-RXR chi- pioglitazone was also a PPARr agonist. In addition to piog- 
mera along with the LBD of either PPARa, PPARy, or litazone, the related thiazolidinedione BRL49653 (see Fig- 
PPARG. By itself, the PPAR LBD cannot bind or activate 
the UASG reporter (data not shown); rather, transactivation 
by an LBD requires prior association with GAL-RXR 
(Forman et al., 1995b). Using this approach, we found that 
when they were tethered to GAL-RXR, the activation of 
PPARa and PPARy by PGJn-related molecules was quali- 
tatively similar to the results already seen with GAL-PPAR 
constructs (Figure 2A). In contrast, when associated with 
GAL-RXR, PPARS acquired a weak ability to respond to 
lSd-PGJz when complexed with RXR (Figure 2B). These 
data indicate that PGJ2 signaling is mediated predomi- 
nantly by PPARy and to a lesser extent by other PPAR- 
RXR heterodimers. 
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Figure 3. The Most Active Derivative of Prostaglandin JZ Is 15d-PGJ2 
(A) The prostaglandin biosynthetic pathway. Arachidonic acid is me- 
tabolized to PGH2, acommon precursor in thesynthesisof most prosta- 
glandins (Smith et al., 1991). PGD* formed in this manner may then 
be converted to PGJ? derivatives, including the ultimate metabolite, 
15d-PGJ2 (Fukushima, 1990). The highlighted pathway is the branch 
involved in converting PGD, to 15d-PGJ*. 
(6) Kinetics of PPARy activation by PGD2 and 15d-PGJ2. CV-1 cells 
were transfected as in Figure 2A. Following transfection, the cells were 
incubated overnight in media and then treated for the indicated times 
with media containing PGD, (10 NM) or 15d-PGJ2 (10 PM). Normalized 
luciferaseactivity wasdetermined and plotted as fold activation relative 
to untreated cells. 
(C) Dose-response of GAL-PPARy LSD to J,-related prostaglandins. 
CV-1 cells were transfected as in Figure 2A and treated with or without 
the indicated concentrations of each prostaglandin. Normalized lucif- 
erase activity was determined and plotted as fold activation relative 
to untreated cells. 
ure 8) (Cantello et al., 1994) had been reported to be a 
PPARS (also known as NUCl and FAAR) activator (Ibra- 
himi et al., 1994). This prompted us to compare the ability 
of thiazolidinediones to activate all three PPAR isoforms. 
Surprisingly, both pioglitazone (Figure 4A) and 
BRL49653 (Figure 48) were very potent activators of GAL- 
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Figure 4. Antidiabetic Thiazolidinediones Activate PPARy 
(A) Activation of GAL-PPAR LBD fusion proteins by pioglitazone. In 
the main panel, CV-1 cells were transfected as in Figure 2A. For the 
inset, cells were transfected as in Figure 28. In both cases, cells were 
treated with the indicated concentrations of pioglitazone. Normalized 
luciferase activity was determined and plotted as fold activation relative 
to untreated cells. 
(B) Activation of GAL-PPAR LBD fusion proteins by ERL49653. This 
experiment is identical to that of (A), except that the transfected cells 
were treated with 6RL49653. 
PPARy, displaying half-maximal activities of >5 pM and 
1 PM, respectively. Thiazolidinediones were preferential 
activators of they isoform, as neither compound exhibited 
significant activation of GAL-PPARa or GAL-PPARS un- 
der these conditions (Figures 4A-4B). Similar specificity 
was observed with troglitazone (CS-045) (data not shown), 
a thiazolidinedione that has been used successfully as an 
antidiabetic in human trials (Nolan et al., 1994). Activation 
appears to be mediated specifically by thiazolidinediones 
with antidiabetic activity, as the weak antidiabetic com- 
pound 66 (see Figure 8) (Cantello et al., 1994) is a poor 
PPARy agonist (data not shown). As with 15d-PGJ2, the 
kinetics of PPARy activation by BRL49653 are rapid 
(within 2 hr; data not shown). These data indicate that 
antidiabetic thiazolidinediones mimic the transcriptional 
activating properties of 1 5d-PGJ2. 
Since we previously found that activation of PPARS was 
augmented by RXR (see Figure 28) we also examined 
the activity of the thiazolidinediones by using PPAR LBDs 
tethered to GAL-RXR. As with 15d-PGJ2, heterodimeriza- 
tion of PPARS with GAL-RXR did facilitate a response to 
thiazolidinediones; however, this heterodimer was lo- to 
lOO-fold less sensitive than the comparable PPARy-RXR 
complex (Figures 4A-4B, inset). These data further sup- 
port the proposal that PPARy is the principal target for the 
antidiabetic thiazolidinediones. 
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Figure 5. Adipogenesis in PPAFiy-Expressing 
Cells Is Induced by 15d-PGJ2 and Thiazoli- 
dinediones 
NIH-PPART cells were cultured in differentia- 
tion media or differentiation media containing 
the indicated concentrations of PPARy activa- 
tors as described in Experimental Procedures. 
After 8 days of confluent culture, cells were 
fixed and stained with oil red 0. 
(A) Macroscopic view of cell culture mates. 
@j Microscopic view at 180 x magnification. 
0.5 UM BRL-49653 
15d-PGJ2 and Thiazolidinediones 
Induce Adipogenesis 
Recent work indicates that PPARy plays a central role in 
adipocyte gene expression and differentiation (Tontonoz 
et al., 1994~). This receptor is expressed at high levels 
specifically in adipose cells, and most importantly, forced 
expression of PPARy is sufficient to convert a number of 
fibroblast cell lines into differentiation-competent preadi- 
pocytes. These observations suggest that PPARy activa- 
tors such as 15d-PGJ2 and thiazolidinediones are likely to 
be important regulators of adipocyte development (Hira- 
gun et al., 1988; Kletzien et al., 1992; Sandouk et al., 
1993). To address this issue, NIH 3T3 cell lines expressing 
PPARy (NIH-PPARy) were established by retroviral infec- 
tion (Tontonoz et al., 1994c) and cultured for 8 days post- 
confluence in either differentiation medium alone (see 
Experimental Procedures) or in differentiation medium 
containing various PPAR activators. Adipocyte differentia- 
tion was assessed morphologically and by the accumula- 
tion of intracellular lipids that stain positive with oil red 0 
(McKinney and Riley, 1967) (Figure 5A, culture dishes; 
Figure 58, micrographs). We demonstrated previously 
that the leukotriene antagonist LY171883 promotes adi- 
pose differentiation of NIH-PPART cells at relatively high 
concentrations (50-l 00 PM) (Tontonoz et al., 1994c). We 
find that 15d-PGJ2 and pioglitazone are dramatically more 
potent and efficacious inducers of adipogenesis, resulting 
in greater than 80% differentiation of the cells at con- 
centrations of 5 uM (Figures 5A-5B). Consistent with the 
transactivation assays, BRL49653 was the most potent 
adipogenic agent, promoting efficient differentiation at 
concentrations as low as 0.5 uM (Figures 5A-5B). No dif- 
ferentiation was observed with any of these compounds 
when control cells (NIH vector) were used (data not 
shown), indicating that their effects on differentiation are 
mediated by PPARy. 
To confirm that 15d-PGJ2, pioglitazone, and BRL49653 
promote true adipose differentiation, we examined the 
ability of these compounds to induce expression of adipo- 
cyte-specific markers (Figure 6). Northern blot analysis 
indicates that NIH-PPARy cells differentiated with 15d- 
PGJ2, pioglitazone, or BRL49653 express high levels of 
the adipocyte-specific mRNAs encoding aP2 and adipsin 
(Figure 6). As expected, control cells (NIH vector) that are 
deficient in PPARy do not express these mRNAs but con- 
tain equivalent amounts of a control transcript (3684, hu- 
man acid ribosomal phosphoprotein PO). 
Thiazolidinediones and 15d-PGJ2 
Are PPARy Ligands 
The ability of thiazolidinediones and 15d-PGJ2 to activate 
transcription with kinetics similar to those of the hormonal 
ligands of other nuclear receptors (see Figure 38; data 
not shown) implies that these compounds may represent 
ligands for the orphan receptor PPARy. To test this possi- 
bility, PPARy was expressed in a bacterial expression sys- 
tem, purified, and assayed for binding of PH]BRL49653. 
As seen in Figure 7A; [3H]BRL49653 bound to PPARy and 
was effectively displaced by an excess of unlabeled 
BRL49653, indicating that binding was specific. Displace- 
ment by other compounds correlated with transcriptional 
activity in transfected cells (see Figure 4), i.e., unlabeled 
BRL49653 was a more effective competitor than pioglita- 
zone, while no competition was observed with compound 
66 (Figure 8) or estradiol. [3H]BRL49653 binding to PPARy 
was dose-dependent and saturable with a dissociation 
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activator (I] in NM) ple of a nuclear receptor for a prostaglandin derivative 
and are consistent with previous reports that PGJa-related 
compounds accumulate in nuclei (Narumiya et al., 1986, 
1987). Thus, PGJ, derivatives appear to be unique among 
prostaglandins, as they can act through a nuclear receptor 
without the requirement of second messenger pathways. 
Our knowledge of the enzymology and regulation of 
PGJ, metabolism remains incomplete (Fukushima, 1990, 
1992). In vitro, PGDz spontaneously converts into PGJ2 
and in the presence of serum or albumin is further con- 
verted to A”-PGJ2 and 15d-PGJ2 (Fitzpatrick and Wy- 
nalda, 1983; Kikawa et al., 1984; Mahmud et al., 1984). 
It is not known whether this pathway is utilized in the organ- 
ism, but it is clear that JZ prostanoids are synthesized in 
vivo. This is based on the observation that A’*-PGJZ is a 
natural component of human body fluids (Hirata et al., 
1988) and that A’*-PGJz synthesis is suppressed by treat- 
ment with cyclooxygenase inhibitors (Hirata et al., 1988). 
The natural precursor to PGJn-derivatives appears to be 
PGD2, since its in vivo administration leads to large in- 
creases in A’*-PGJ2 (Hirata et al., 1988). Since PGD, is the 
major prostaglandin in most tissues (Fukushima, 1990), it 
is possible that PGJ2 derivatives may be produced at a 
number of sites. It is unknown whether 1 Sd-PGJz is synthe- 
sized in PPARy-expressing tissues or whether it is synthe- 
sized elsewhere and transported to its target tissues. An 
elucidation of the natural sites of 15d-PGJ2 production will 
be required in order to determine whether 15d-PGJ2 acts 
as an endocrine, paracrine, or intracrine signal, or any 
combination of these (O’Malley, 1989). Finally, it remains 
possible that other endogenous 15d-PGJ~related prosta- 
glandins may act as ligands for PPARy. Thus, the identifi- 
cation of 15d-PGJz as a PPARy ligand should stimulate 
further research into the biochemistry and adipogenic ac- 
tivities of potentially other Jz-related prostaglandins. 
Our studies indicate that micromolar doses of 1 Sd-PGJP 
can initiate PPARy-dependent adipogenesis. Although 
physiologic concentrations of 15d-PGJ2 have not been es- 
tablished, previous studies have shown that PGJ2 metabo- 
lites mediate other activities at similar doses. For example, 
PGJ2 metabolites induce cell cycle arrest (Fukushima, 
1990) and apoptosis (Kim et al., 1993) at micromolar 
doses. Since PPARy-specific thiazolidinediones do not 
possess similar cytotoxic activities (unpublished data), it 
is possible that these effects are mediated by other PGJz 
metabolites, other receptors, or both. In particular, our 
observation that PPARG-RXR heterodimers are activated 
by 15d-PGJ2 (Figure 28) and PGJ* (6. M. F. and R. M. E., 
unpublished data) implicates PPARG as a potential candi- 
date in mediating these activities. 
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Figure 6. Expression of Adipocyte-Specific Markers Is Induced by 
15d-PGJ2 and Thiazolidinediones 
NIH-PPARy cells were treated as in Figure 5 with the indicated concen- 
tration of each activator. The concentration of each activator, in micro- 
molar units (KM), is indicated in parentheses above each lane. Total 
RNA (10 ug per lane) was then isolated, fractionated by electrophore- 
sis, blotted onto nylon membranes, and hybridized with the indicated 
32P-labeled probe. aP2, adipocyte fatty acid-binding protein: 3684, 
human acid ribosomal phosphoprotein PO. 
constant (Kd) of 325 nM (Figure 7B). In addition, BRL49653 
represents a PPARy-specific ligand, since [3H]BRL49653 
did not bind specifically to PPARa, PPARG, RXRa, TaRa, 
or other proteins, such as ovalbumin, hemoglobin, or glu- 
tathione S-transferase (GST) (data not shown). 
We next sought to examine whether 15d-PGJ2 also 
bound to PPARy by testing the ability of unlabeled prostan- 
oids to compete with [3H]BRL49653 (Figure 7C). This is 
particularly important, since natural ligands for any of the 
PPAR isoforms have been elusive. 15d-PGJ2 effectively 
competed for [3H]BRL49653 binding, indicating that it is 
a direct ligand for PPARy. Consistent with the activation 
profiles observed in transfection assays (see Figures 2A 
and 3C), some competition was also observed with PGJ2 
and A”-PGJ2. As expected, prostanoids that failed to acti- 
vate PPARy (see Figure 2A) also failed to displace 
13H]BRL49653 (Figure 7C), indicating that binding of 
PPARy to 15d-PGJ2 is highly specific. These data provide 
compelling evidence that 15d-PGJ2 is a biological ligand 
for the adipocyte determination factor PPARy. 
Discussion 
A Nuclear Prostanoid Receptor 
We demonstrate here that the nuclear transcription factor 
PPARy is a receptor for adipogenic prostanoids and antidi- 
abetic thiazolidinediones. The identification of 15d-PGJ2 
as a natural PPARy ligand suggests a novel role for J2 
prostanoids in a molecular pathway leading to adipogen- 
esis. Previously identified prostanoid receptors are local- 
ized on the cell surface and act through second messenger 
systems (Narumiya, 1995). Our findings provide an exam- 
PPARy and Insulin Resistance 
Individuals with NIDDM have a pronounced postreceptor 
defect in insulin signaling, resulting in impaired insulin 
responsiveness in peripheral tissues. Thiazolidinediones 
are a class of antidiabetic drugs that exhibit insulin- 
sensitizing activity in mice and humans (Cantello et al., 
1994; Hofmann and Colca, 1992; Nolan et al., 1994). We 
have shown here that antidiabetic thiazolidinediones se- 
lectively activate PPARy and are potent inducers of adi- 
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Figure 7. Thiazolidinediones and 15d-PGJ2 Are PPARy Ligands 
(A) Binding of [3H]BRL49653 to PPARy is specifically displaced by 
an excess of unlabeled BRL49653 and pioglitazone. For each point, 
approximately 400 ng of purified bacterially expressed PPARy was 
incubated with 500 nM of [3H]BRL49653 with carrier (dash, DMSO) 
or with the following unlabeled competitors: BRL49653,50 NM; piogli- 
tazone, 50 wM; compound 66,50 PM; or estradiol, 100 @M. After incu- 
bation, [3H]BRL49853 bound to PPARy was separated from the free 
label (see Experimental Procedures) and quantified by liquid scintilla- 
tion counting. We assigned 100% binding as the amount of 
[3H]BRL49653 bound to PPARy in the presence of carrier; this repre- 
sented 7998 r 320 cpm. Background binding of [3H]BRL49653 to 
nonspecific protein (GST) was less than 100 cpm. Each point repre- 
sents the average of duplicate samples. 
(B) Scatchard analysis of [3H]BRL49653 binding to PPARy. For each 
point, approximately 800 ng of purified bacterially expressed PPARy 
was incubated with the indicated concentration of [3H]BRL49653. The 
amountofspecificallybound [3H]BRL49653wasdetermined inquadru- 
plicate samples. Scatchard analysis was performed by replotting the 
data as shown in the inset. Linear regression of this data revealed a 
Kd of 325 nM. 
(C) Binding of [3H]BRL49653 to PPARy is specifically displaced by an 
excess of unlabeled 15d-PGJz. For each point, approximately 300 ng 
of purified bacterially expressed PPARy was incubated with 320 nM 
[3H]BRL49653 in the presenceof carrier(dash) or the following concen- 
trations of unlabeled competitors: 50 pM (PGDZ, PGJ2, A’Z-PGJ2, and 
15d-PGJ2) or 100 WM (PGBz, PGE,, PGF*,, Sa,llB-PGF, PGI,, and 
PGK*). The amount PH]BRL49653 bound to PPARy was then deter- 
mined (see Experimental Procedures). We assigned 100% binding as 
the amount of rHlBRL49653 bound to PPARy in the presence of car- 
rier; this represented 25,966 + 121 cpm. Each point represents the 
average of duplicate samples. 
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Figure 8. Chemical Structures of PPARy Ligands and Activators 
This figure compares the chemical structures of PPARy activators 
including LY171883, the antidiabetic thiazolidinediones (top), and J1- 
related prostanoids (bottom). We show here that BRL49653, pioglita- 
zone, and 15d-PGJ2 are ligands for PPARy. 
pogenesis. Similar results have been reported recently 
(Lehmann et al., 1995). Taken together, these results show 
a correlation between PPARy binding affinity and the 
antidiabetic potency of six different thiazolidinediones 
(BRL49653 > troglitazone > pioglitazone > ciglitazone > 
englitazone > compound 66). The identification of PPARy 
as a target of these drugs suggests that this receptor (or 
its downstream genes) may mediate or enhance insulin 
responsiveness. 
An alternative possibility is that PPARy may negatively 
regulate an inhibitor of insulin action such as TNFu. In- 
deed, several lines of evidence link this cytokine to the 
development of NIDDM. First, TNFa is expressed in adipo- 
cytes, and its levels are elevated in obesity and NIDDM 
(Hotamisligil et al., 1993, 1994, 1995; McCall et al., 1992). 
Second, neutralization of TNFa improves insulin signaling 
in vivo (Hotamisligil et al., 1993; Hotamisligil and Spiegel- 
man, 1994). Finally, excess TNFa can suppress insulin- 
induced phosphorylation of the insulin receptor substrate 
1 (Feinstein et al., 1993; Hofmann et al., 1994; Hotamisligil 
et al., 1994). These observations lead to the prediction 
that manipulations suppressing TNFa activity could result 
in diminished insulin resistance. It is therfore interesting 
to note that antidiabetic thiazolidinediones inhibit TNFa 
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action (Ohsumiet al., 1994; Szalkowskiet al., 1995). Thus, 
the antidiabetic properties of thiazolidinediones could be 
related, in part, to the ability of these compounds to reduce 
expression of TNFa and one of its receptors in insulin- 
resistant animals (Hofmann et al., 1994). Future studies 
will be required to understand the molecular mechanisms 
that link PPARy activity to the insulin signaling pathway. 
Implications for Drug Discovery 
The identification of 1 5d-PGJ2 as a ligand for PPARy impli- 
cates a novel signaling pathway in the development of 
adipose cells. This suggests that alterations in 15d-PGJ2 
levels or inherited mutations in PPARy could play a role 
in the development of obesity or lipodystrophy. In addition, 
the observation that PPARy is a common receptor for 15d- 
PGJ2 and thiazolidinediones suggests that PGJ2 metabo- 
lites may function as endogenous mediators of insulin ac- 
tion. This raises the intriguing possibility that defects in 
15d-PGJn-PPARy signaling may contribute to the patho- 
genesis of NIDDM. Thus, screening for potent PPARy ago- 
nists and antagonists represents a logical and potentially 
rapid approach toward thedevelopment of novel therapeu- 
tic agents for NIDDM and obesity, respectively. 
In summary, we provide evidence that a common nu- 
clear signaling pathway mediates the effects of adipogenic 
prostanoids and antidiabetic thiazolidinediones. This sug- 
gests a pivotal role for PPARy and its endogenous ligand in 
adipocyte development and glucose homeostasis. These 
observations open important avenues for future research 
and illustrate how an understanding of orphan nuclear re- 
ceptors can provide valuable insights into normal and ab- 
errant physiology. 
Experimental Procedures 
Chemical Reagents 
LG89 (4-[1-(3,5,5,8,&pentamethyl-5,6,7,8-tetrahydro-Z-naphthyl) ethen- 
yllbenzoic acid) was obtained from R. Heyman (Ligand Pharma- 
ceuticals). Pioglitazone (5-[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4- 
thiazolidinedione; AD-4833; U-72,107) was provided by R. Kletzien 
(Upjohn). All other compounds were obtained through commercial 
sources. These includethefollowing: BRL49653(5-[[4-[2-(methyl-2-pyridi- 
nylamino)ethoxy]phenyl]-methyl]-2,4-thiaolidinedione) and compound 
66 ((~-5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]- methylenel-2, 
4-thiazolidinedione), from Biomol; LY171883 (2-hydroxy-3-propyl-4- 
[4-(tetrazol-5-yl)butoxy]acetophenone), from Biomol; and Wyl4,643 
(4-chloro-[6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid), from Chem- 
syn. All prostaglandins were from Cayman or Biomol, and arachidonic 
acid was from Sigma. 
Plasmids 
For luciferase assays, response elements were cloned into a TK-LUC 
reporter that contains the herpes virus thymidine kinase promoter 
(-105/+51). Response elements with the underlined consensus se- 
quence are as follows: UA& x 4 (5’-CGACGGAGTACTGTCCTCC- 
GAGCT, four copies) and PPRE x 3 (5’-GTCGACAGGGGACCAGGA- 
CAAAGGTCACGTTCGGGAGTCGAC, three copies). Unless stated 
otherwise, mammalian expression vectors were derived from 
pCMX, which contains the cytomegalovirus promoter-enhancer fol- 
lowed by a bacteriophage T7 promoter for transcription in vitro. GAL4 
fusions were made by fusing the following receptor LBDs to the 
C-terminal end of the yeast GAL4 DBD (amino acids l-147) from 
pSG424 (Sadowski and Ptashne, 1989): human RXRa LBD (Glu-203- 
Thr-462) (Forman et al., 1995b); mouse PPARa LBD (Ser-167-Tyr- 
468); mouse PPARyl LBD (Cys-l63-Tyr-475); mouse PPARG LBD 
(Cys-127-Tyr-440). The LBD expression constructs contain the SV40 
TAg nuclear localization signal (APKKKRKVG) fused upstream of the 
same LBD fragments described above. Dominant negative RXR mu- 
tants included the RXR LBD (Forman et al., 1995b) and RS-RXR 443’, 
an expression vector utilizing the Rous sarcoma virus long terminal 
repeat to drive expression of a human RXRa mutant lacking the C- 
terminal transactivation domain (Schulman et al., 1995). RXR 443* 
extends from amino acid Met-l to Gly-443 and contains an Ile-Gln 
substitution at position 442 (prepared by D. Mangelsdorf and R. Hey 
man). For expression of a nuclear localized calreticulin derivative, the 
signal sequence was removed by PCR amplification of sequences 
encoding the mature human calreticulin protein (Glu-18-Leu-417) and 
fused, in-frame, downstream of the yeast GAL4-DBD. CMX+gal con- 
tains the Escherichia coli p-galactosidase coding sequences derived 
from pCH1 IO (Pharmacia). For bacterial expression of PPARy, a con- 
struct containing the full-length mouse PPARyl (Met-l-Tyr-475)fused 
to GST (pGEX-KG-mPPARyl) was obtained from C. Glass and J. 
DiRenzo. 
Transient Transfection Assay 
CV-1 cells were grown as described (Forman et al., 1995a, 1995b, 
and references in the latter) in Dulbecco’s modified Eagle’s medium 
supplemented with 10% resin-charcoal-stripped fetal bovine serum, 
50 U/ml penicillin G, and 50 pg/ml streptomycin sulfate (DMEM-FBS) 
at 37’C in 5% COz. One day prior to transfection, cells were plated 
to 50%-80% confluence with phenol red-free DMEM-FBS. Cells were 
transfected by lipofection using N-[1-(2,3-dioleoyloxy)propyl]-N,N,N- 
ammonium methyl sulfate (DOTAP) according to the instructions of 
the manufacturer (Boehringer Mannheim). After 2 hr, the liposomes 
were removed and cells treated for approximately 40 hr with phenol 
red-free DMEM-FBS alone or with the indicated compounds. For the 
time course studies (Figure 3B), the cells were exposed to media over- 
night and then treated with PGD, or 15d-PGJ2 for the length of time 
indicated. After exposure to ligand, the cells were harvested and as- 
sayed for luciferase and 8-galactosidase activity. All points were per- 
formed in triplicate and varied by less than 10%. Each experiment 
was repeated three or more times with similar results. 
Adipocyte Differentiation Assays 
Differentiation assays were performed with materials and reagents as 
previously described (Tontonoz et al., 1994c, and references therein). 
In brief, BOSC23 cells were cultured in 90 mm dishes and transfected 
at 80% confluence by calcium phosphate coprecipitation with 15 wg 
of pBabe-PPARy M1 or pBabe-Puro expression plasmid as described. 
Viral supernatants were harvested 48 hr after transfection. NIH 3T3 
cells were infected at 50% confluence with equal titers of each recom- 
binant virus (typically 5 x 105), and infected cells were selected with 
puromycin. Stable cell lines were cultured to confluence in differentia- 
tion medium (DMEM containing 10% Cosmic Calf Serum [Hyclone] 
and 5 pglml insulin). At confluence, cells were treated for 48 hr with 
1 PM dexamethasone. PPAR activators were added to the media at 
confluence in a minimal volume of DMSO or methyl acetate as indi- 
cated. Cells were refed every 24 hr, and at 8 days postconfluence, 
either total RNA was isolated, or cells were fixed with formalin and 
stained with oil red 0. 
RNA Analysis 
RNA extraction and analysis was performed as described (Tontonoz 
et al., 1994c, and references therein). In brief, total RNA was isolated 
from cultured cells by guanidine isothiocyanate extraction. RNA was 
blotted to BioTrans nylon membranes (ICN), and membranes were 
cross-linked, hybridized, and washed as directed by the manufacturer. 
To control for equivalency of RNA loading and transfer, all blots were 
hybridized with the cDNA for human acid ribosomal phosphoprotein 
PO (3684). cDNA probes were labeled with [&*P]dCTP (6000 Gil 
mmol) by the random priming method to a specific activity of at least 
1 O9 cpmlvg. 
Ligand Binding Assays 
Ligand binding assays were performed with a GST-mPPARy1 fusion 
protein that was expressed in E. coli and purified by affinity chromatog- 
raphy on glutathione-Sepharose beads. Following elution with gluta- 
thione, the purified protein was extensively dialyzed, and the GST 
moiety was cleaved away with thrombin. The GST protein was then 
removed by a second round of glutathione-Sepharose chromatogra- 
phy followed by extensive dialysis. Ligand binding assays were per- 
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formed by incubating PPARy and 13H]BRL49653 (31 Cilmmol) in a 
buffer containing 10 mM Tris (pH 8.0) 50 mM KCI, and 10 mM DTT. 
Competitor ligands or solvent carrier were added as indicated. For 
experiments with prostaglandin competitors, ovalbumin was added to 
a final concentration of 200 nglul. Binding reactions were incubated 
for 30 min at 25°C and then chilled to 4OC for 15 min. Free and bound 
ligand were separated as described (Forman and Samuels, 1991) by 
using a spin column containing a suspension of Sephadex G-25 
(Sigma) in 15% glycerol, 25 mM Tris (pH 7.8) 0.05% Triton X-100, 
0.5 mM EDTA, and 75 mM KCI. The amount of bound [3H]BRL49653 
was determined by liquid scintillation counting. Each point represents 
the average of duplicate (displacement analysis) or quadruplicate 
(Scatchard analysis) samples. Each experiment was repeated three 
or more times with similar results, 
Acknowledgments 
Correspondence should be addressed to R. M. E. The authors would 
like to thank Rolf Kletzien (Upjohn) for pioglitazone, Rich Heyman 
(Ligand Pharmaceuticals) for LG69, and Christopher Glass and Jim 
DiRenzo for a construct containing mouse PPARyl in pGEX-KG. Cal- 
reticulin cDNAs were provided by Vincent Giguere and Marek Micha- 
lak. We thank Rich Heyman, Kaz Umesono, Mike McKeown, David 
No, and members of the Evans laboratory for comments and sugges- 
tions. R. M. E. is an Investigator of the Howard Hughes Medical Insti- 
tute at the Salk Institute for Biological Studies. This work was sup- 
ported by the Howard Hughes Medical Institute (R. M. E.), the March 
of Dimes (R. M. E.) and DK-31405 (B. M. S.), the Tobacco-Related 
Disease Research Program (6. M. F.), and National Research Service 
Awards T32 GM07753 (P. T.) and DK09090 (R. P. 8). 
Received September 5, 1995; revised October 10, 1995 
References 
Boehm, M.F., McClurg, MR., Pathirana, C., Mangelsdorf, D., White, 
SK., Hebert, J., Winn, D., Goldman, M.E., and Heyman, R.A. (1994). 
Synthesis of high specific activity [3H]-9-cis-retinoic acid and its appli- 
cation for identifying retinoids with unusual binding properties. J. Med. 
Chem. 37, 408-414. 
Burns, K., Duggan, B., Atkinson, E.A., Famulski, KS., Nemer, M., 
Bleackley, R.C., and Michalak, M. (1994). Modulation of gene expres- 
sion by calreticulin binding to the glucocorticoid receptor. Nature 367, 
476-480. 
Campfield, L.A., Smith, F.J., Guisez, Y., Devos, R., and Burn, P. 
(1995). Recombinant mouse Ob protein: evidence for a peripheral 
signal linking adiposity and central neural networks. Science 269,546- 
549. 
Cantello, B.C., Cawthorne, M.A., Cottam, G.P., Duff, P.T., Haigh, D., 
Hindley, R.M., Lister, C.A., Smith, S.A., and Thurlby, P.L. (1994). ([D- 
(Heterocyclylamino)aIkoxy]benzyl)-2,4- thiazolidinediones as potent 
antihyperglycemic agents. J. Med. Chem. 37, 3977-3985. 
Chawla, A., Schwarz, E.J., Dimaculangan, D.D., and Lazar, M.A. 
(1994). Peroxisome proliferator-activated receptor (PPAR) y: adipose- 
predominant expression and induction early in adipocyte differentia- 
tion. Endocrinology 735, 798-800. 
Dedhar, S., Rennie, P.S., Shago, M., Hagesteijn, C.Y., Yang, H., Fil- 
mus, J., Hawley, R.G., Bruchovsky, N., Cheng, H., Matusik, R.J., et al. 
(1994). Inhibition of nuclear hormone receptor activity by calreticulin. 
Nature 367, 480-483. 
Evans, R.M. (1988). The steroid and thyroid hormone receptor super- 
family. Science 240, 889-895. 
Feinstein, R., Kanety, H., Papa, M.Z., Lunenfeld, B., and Karasik, A. 
(1993). Tumor necrosis factor-a suppresses insulin-induced tyrosine 
phosphorylation of insulin receptor and its substrates. J. Biol. Chem. 
268, 2605526058. 
Fitzpatrick, F.A., and Wynalda, M.A. (1983). Albumin-catalyzed metab- 
olism of prostaglandin D2. Identification of products formed in vitro. 
J. Biol. Chem. 258, 11713-11718. 
Flier, J.S. (1995). The adipocyte: storage depot or node on the energy 
information superhighway? Cell 80, 15-18. 
Forman, B.M., and Samuels, H.H. (1990). Interactions among a sub- 
family of nuclear hormone receptors: the regulatory zipper model. Mol. 
Endocrinol. 4, 1293-l 301. 
Forman, B.M., and Samuels, H.H. (1991). pEXPRESS: a family of 
expression vectors containing a single transcription unit active in pro- 
karyotes, eukaryotes and in vitro. Gene 705, 9-15. 
Forman, B.M., Goode, E., Chen, J., Oro,A.E., Bradley, D.J., Perlmann, 
T., Noonan, D.J., Burka, L.T., McMorris, T., Lamph, W.W., Evans, 
R.M., and Weinberger, C. (1995a). identification of a nuclear receptor 
that is activated by farnesol metabolites. Cell 87, 687-693. 
Forman, B.M., Umesono, K., Chen, J., and Evans, R.M. (1995b). 
Unique response pathways are established by allosteric interactions 
among nuclear hormone receptors. Cell 87, 541-550. 
Foxworthy, P.S., and Eacho, P.I. (1988). Inhibition of hepatic fatty 
acid oxidation at carnitine palmitoyltransferase I by the peroxisome 
proliferator P-hydroxy-3-propyl-4-[6-(tetrazol-5-yl) hexyloxylacetophe- 
none. Biochem. J. 252, 409-414. 
Fukushima, M. (1990). Prostaglandin J2: anti-tumour and anti-viral ac- 
tivities and the mechanisms involved. Eicosanoids 3, 189-199. 
Fukushima, M. (1992). Biological activities and mechanisms of action 
of PGJ* and related compounds: an update. Prostaglandins Leukot. 
Essent. Fatty Acids 47, 1-12. 
Gottlicher, M., Widmark, E., Li, Q., and Gustafsson, J.A. (1992). Fatty 
acids activate a chimera of the clofibric acid-activated receptor and 
the glucocorticoid receptor. Proc. Natl. Acad. Sci. USA 89,4653-4657. 
Grundy, S.M., and Barnett, J.P. (1990). Metabolicand health complica- 
tions of obesity. Dis. Mon. 36, 641-731. 
Gulick, T., Cresci, S., Caira, T., Moore, D.D., and Kelly, D.P. (1994). 
The peroxisome proliferator-activated receptor regulates mitochon- 
drial fatty acid oxidative enzyme gene expression. Proc. Natl. Acad. 
Sci. USA 97, 11012-11016. 
Halaas, J.L., Gajiwala, K.S., Maffei, M., Cohen, S.L., Chait, B.T., Rabi- 
nowitz, D., Lallone, R.L., Burley, S.K., and Friedman, J.M. (1995). 
Weight-reducing effects of the plasma protein encoded by the obese 
gene. Science 269, 543-546. 
Harris, P.K., and Kletzien, R.F. (1994). Localization of a pioglitazone 
response element in the adipocyte fatty acid-binding protein gene. 
Mol. Pharmacol. 45, 439-445. 
Heyman, R.A., Mangelsdorf, D.J., Dyck, J.A., Stein, R.B., Eichele, G., 
Evans, R.M., and Thaller, C. (1992). 9-cis retinoic acid is a high affinity 
ligand for the retinoid X receptor. Cell 68, 397-406. 
Hiragun, A., Sato, M., and Mitsui, H. (1988). Preadipocyte differentia- 
tion in vitro: identification of a highly active adipogenic agent. J. Cell 
Physiol. 734, 124-130. 
Hirata, Y., Hayashi, H., Ito, S., Kikawa, Y., Ishibashi, M., Sudo, M., 
Miyazaki, H., Fukushima, M., Narumiya, S., and Hayaishi, 0. (1988). 
Occurrence of 9-deoxy-Aq,A’Z-13,14-dihydroprostaglandin Dz in hu- 
man urine. J. Biol. Chem. 263, 16619-16625. 
Hofmann, C., Lorenz, K., Braithwaite, S.S., Colca, J.R., Palazuk, B.J., 
Hotamisligil, G.S., and Spiegelman, B.M. (1994). Altered geneexpres- 
sion for tumor necrosis factor-a and its receptors during drug and 
dietary modulation of insulin resistance. Endocrinology 734, 264-270. 
Hofmann, C.A., and Colca, J.R. (1992). New oral thiazolidinedione 
antidiabetic agents act as insulin sensitizers. Diabetes Care 75,1075- 
1078. 
Hotamisligil, G.S., Shargill, N.S., and Spiegelman, B.M. (1993). Adi- 
poseexpression of tumor necrosis factor-a: direct role in obesity-linked 
insulin resistance. Science 259, 87-91. 
Hotamisligil, G.S., Budavari, A., Murray, D., and Spiegelman, B.M. 
(1994). Reduced tyrosine kinase activity of the insulin receptor in obe- 
sity-diabetes: central role of tumor necrosis factor-a. J. Clin. Invest. 
94, 1543-l 549. 
Hotamisfigil, G.S., and Spiegelman, B.M. (1994). Tumor necrosis fac- 
tor a: a key component of the obesity-diabetes link. Diabetes 43, 
1271-1278. 
Hotamisfigil, G.S., Arner, P., Caro, J.F., Atkinson, R.L., and Spiegel- 
man, B.M. (1995). Increased adipose tissue expression of tumor necro- 
sis factor-a in human obesity and insulin resistance. J. Clin. Invest. 
95, 2409-2415. 
Cell 
812 
Ibrahimi, A., Teboul, L., Gaillard, D., Amri, E.Z.,Ailhaud, G., Young, P., 
Cawthorne, M.A., and Grimaldi, P.A. (1994). Evidence for a common 
mechanism of action for fatty acids and thiazolidinedione antidiabetic 
agents on gene expression in preadipose cells. Mol. Pharmacol. 46, 
1070-1076. 
Issemann, I., and Green, S. (1990). Activation of a member of the 
steroid hormone receptor superfamily by peroxisome proliferators. Na- 
ture 347, 645-650. 
Keller, H., Dreyer, C., Medin, J., Mahfoudi, A., Ozato, K., and Wahli, 
W. (1993). Fatty acids and retinoids control lipid metabolism through 
activation of peroxisome proliferator-activated receptor-retinoid X re- 
ceptor heterodimers. Proo. Natl. Acad. Sci. USA 90, 2160-2164. 
Kikawa, Y., Narumiya, S., Fukushima, M., Wakatsuka, H., and Hay- 
aishi, 0. (1984). 9-Deoxy-A9,A’2-13,14-dihydroprostaglandin DP, a me- 
taboliteof prostaglandin D,formed in human plasma. Proc. Natl. Acad. 
Sci. USA 87, 1317-1321. 
Kim, I.K., Lee, J.H., Sohn, H.W., Kim, H.S., and Kim, S.H. (1993). 
Prostaglandin A2 and A12-prostaglandin Jz induce apoptosis in L1210 
cells. FEES Lett. 321, 209-214. 
Kletzien, RF., Clarke, S.D., and Ulrich, R.G. (1992). Enhancement of 
adipocyte differentiation by an insulin-sensitizing agent. Mol. Pharma- 
~01. 41, 393-398. 
Kliewer, S.A., Umesono, K., Noonan, D.J., Heyman, R.A., and Evans, 
R.M. (1992). Convergence of 9-cis retinoic acid and peroxisome prolif- 
erator signalling pathways through heterodimer formation of their re- 
ceptors. Nature 358, 771-774. 
Kliewer, S.A., Forman, B.M., Blumberg, B., Ong, ES., Borgmeyer, U., 
Mangelsdorf, D.J., Umesono, K., and Evans, R.M. (1994). Differential 
expression and activation of a family of murine peroxisome prolifera- 
tor-activated receptors. Proc. Natl. Acad. Sci. USA 97, 7355-7359. 
Kuczmarski, R.J., Flegal, K.M., Campbell, S.M., and Johnson, CL. 
(1994). Increasing prevalence of overweight among US adults: the 
national health and nutrition examination surveys, 1960 to 1991. J. 
Am. Med. Sot. 272, 205-21 I, 
Kurokawa, R., DiRenzo, J., Boehm, M., Sugarman, J., Gloss, B., Ro- 
senfeld, M.G., Heyman, R.A., and Glass, C.K. (1994). Regulation of 
retinoid signalling by receptor polarity and allosteric control of ligand 
binding. Nature 377, 528-531. 
Lehmann, J.M., Moore, L.B., Smith-Oliver, T.A., Wilkison, W.O., Will- 
son, T.M., and Kliewer, S.A. (1995). An antidiabetic thiazolidinedione 
is a high affinity ligand for peroxisome proliferator-activated receptor 
y. J. Biol. Chem. 270, 12953-12956. 
Levin, A.A., Sturzenbecker, L.J., Kazmer, S., Bosakowski, T., Husel- 
ton, C., Allenby, G., Speck, J., Kratzeisen, C., Rosenberger, M., Lovey, 
A., et al. (1992). 9-cis retinoic acid stereoisomer binds and activates 
the nuclear receptor RXRa. Nature 355, 359-361. 
Mahmud, I., Smith, D.L., Whyte, M.A., Nelson, J.T., Cho, D., Tokes, 
L.G., Alvarez, R., and Willis, A.L. (1984). On the identification and 
biological properties of prostaglandin J2. Prostaglandins Leukot. Med. 
76, 131-146. 
Mangelsdorf, D.J., Umesono, K., Kliewer, S.A., Borgmeyer, U., Ong, 
E.S., and Evans, R.M. (1991). A direct repeat in the cellular retinol- 
binding protein type II gene confers differential regulation by RXR and 
RAR. Cell 66, 555-561. 
Marshall, W.S., Goodson, T., Cullinan, G.J., Swanson-Bean, D., 
Haisch, K.D., Rinkema, L.E., and Fleisch, J.H. (1987). Leukotriene 
receptor antagonists. I. Synthesis and structure-activity relationships 
of alkoxyacetophenone derivatives. J. Med. Chem. 30, 682-689. 
McCall, J.L., Tuckey, J.A., and Parry, B.R. (1992). Serum tumour ne- 
crosis factor a and insulin resistance in gastrointestinal cancer. Br. 
J. Surg. 79, 1361-1363. 
McKinney, B., and Riley, M. (1967). An orcein-oil red 0 stain for con- 
comitant demonstration of elastic tissue and lipid. Stain Technol. 42, 
245-248. 
Narumiya, S. (1995). Structures, properties and distributions of 
prostanoid receptors, Adv. Prostaglandin Thromboxane Leukot. Res. 
23, 17-22. 
Narumiya, S., Ohno, K., Fujiwara, M., and Fukushima, M. (1986). Site 
and mechanism of growth inhibition by prostaglandins. II. Tempera- 
ture-dependent transfer of a cyclopentenone prostaglandin to nuclei. 
J. Pharmacol. Exp. Ther. 239, 506-511. 
Narumiya, S., Ohno, K., Fukushima, M., and Fujiwara, M. (1987). Site 
and mechanism of growth inhibition by prostaglandins. Ill. Distribution 
and binding of prostaglandin AP and A12-prostaglandin Jp in nuclei. 
J. Pharmacol. Exp. Ther. 242, 306-311. 
Nolan, J.J., Ludvik, B., Beerdsen, P., Joyce, M., and Olefsky, J. (1994). 
Improvement in glucose tolerance and insulin resistance in obese sub- 
jects treated with troglitazone. N. Engl. J. Med. 331, 1188-1193. 
Ohsumi, J., Sakakibara, S., Yamaguchi, J., Miyadai, K., Yoshioka, 
S., Fujiwara, T., Horikoshi, H., and Serizawa, N. (1994). Troglitazone 
prevents the inhibitory effects of inflammatory cytokines on insulin- 
induced adipocyte differentiation in 3T3-Ll cells. Endocrinology 735, 
2279-2282. 
O’Malley, B.W. (1989). Did eucaryotic steroid receptors evolve from 
intracrine gene regulators? Endocrinology 725, 1119-l 120. 
Palmer, C.N.A., Hsu, M.H., Griffin, K.J., and Johnson, E.F. (1995). 
Novel sequence determinants in peroxisome proliferator signaling. J. 
Biol. Chem. 270, 16114-16121. 
Pelleymounter, M.A., Cullen, M.J., Baker, M.B., Hecht, R., Winters, 
D., Boone, T., and Collins, F. (1995). Effects of the obese gene product 
on body weight regulation in OblOb mice. Science 269, 540-543. 
Sadowski, I., and Ptashne, M. (1989). A vector for expressing GAL4 
(1-147) fusions in mammalian cells. Nucl. Acids Res. 77, 7539. 
Sandouk, T., Reda, D., and Hofmann, C. (1993). Antidiabetic agent 
pioglitazone enhances adipocyte differentiation of 3T3-F442A cells. 
Am. J. Physiol. 264, C1600-C1608. 
Schulman, I.G., Chakravarti, D., Jugilon, H., Romo, A., and Evans, 
R.M. (1995). Interactions between retinoid X receptor and a conserved 
regionof theTATA-binding protein mediate hormone-dependenttrans- 
activation. Proc. Natl. Acad. Sci. USA 92, 8288-8292. 
Smith, W.L., Marnett, L.J., and Dewitt, D.L. (1991). Prostaglandin and 
thromboxane biosynthesis. Pharmacol. Ther. 49, 153-179. 
Sohda, T., Momose, Y., Meguro, K., Kawamatsu, Y., Sugiyama, Y., 
and Ikeda, H. (1990). Studies on antidiabetic agents. Synthesis and 
hypoglycemic activity of 5-]4-(pyridylalkoxy)benzyl]-2,4-thiazolidinedi- 
ones. Arzneimittelforschung 40, 37-42. 
Szalkowski, D., White-Carrington, S., Berger, J., and Zhang, B. (1995). 
Antidiabetic thiazolidinediones block the inhibitory effect of tumor ne- 
crosis factor-a on differentiation, insulin-stimulated glucose uptake, 
and gene expression in 3T3-Ll cells. Endocrinology 736, 1474-1481. 
Tontonoz, P., Graves, R.A., Budavari, A.I., Erdjument-Bromage, H., 
Lui, M., Hu, E., Tempst, P., and Spiegelman, B.M. (1994a). Adipocyte- 
specific transcription factor ARF6 is a heterodimeric complex of two 
nuclear hormone receptors, PPARy and RXRa. Nucl. Acids Res. 22, 
5628-5634. 
Tontonoz, P., Hu, E., Graves, R.A., Budavari, A.I., and Spiegelman, 
B.M. (1994b). mPPARy2: tissue-specific regulator of an adipocyte en- 
hancer. Genes Dev. 8, 1224-1234. 
Tontonoz, P., Hu, E., and Spiegelman, B.M. (1994c). Stimulation of 
adipogenesis in fibroblasts by PPARy2, a lipid-activated transcript/on 
factor. Cell 79, 1147-l 156. 
Yao, T.P., Forman, B.M., Jiang, Z., Cherbas, L., Chen, J. D., 
McKeown, M., Cherbas, P., and Evans, R.M. (1993). Functional ecdy- 
sone receptor is the product of EcR and Ultraspiracle genes. Nature 
366, 476-479. 
